by Team Small News | Sep 22, 2025 | Cipla, Pharma
Indian pharmaceutical company Cipla is reportedly preparing for a significant management change. Umang Vohra, the company’s managing director and global CEO, is expected to step down by the end of the current fiscal year. Vohra, 54, has been in the role for... by Team Small News | Sep 20, 2025 | Cipla, Pharma
Teva Pharmaceutical Industries Ltd. has reached a settlement agreement to dismiss its patent-infringement lawsuit against Cipla Ltd., an Indian generic-drug maker, over proposed copies of its Qvar RediHaler asthma treatment. The agreement was approved by Judge Stanley...
by Team Small News | Sep 14, 2025 | Aurobindo Pharma, Biocon, Cipla, Glenmark, Lupin, Mankind, Pharma, Sun Pharma, Torrent Pharma, Zydus
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities....
by Team Small News | Sep 8, 2025 | Cipla, Lupin, Mankind, Pharma, Sun Pharma
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and...
by Team Small News | Aug 26, 2025 | Aurobindo Pharma, Cipla, Lupin, Pharma, Sun Pharma
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce... by Team Small News | Aug 25, 2025 | Cipla, Glenmark, Lupin, Mankind, Pharma
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and...